Amneal Pharmaceuticals Inc (AMRX)
NASDAQ:AMRX
Want to see AMRX full AI Analyst Report?
Earnings Data
Report Date
Aug 12, 2026Before Open (Confirmed)
Period Ending
2026 (Q2)Consensus EPS Forecast
0.23Last Year’s EPS
0.25Same Quarter Last Year
Strong Buy
Based on 5 Analysts Ratings
Earnings Call Summary
Q1 2026
Earnings Call Date:May 01, 2026|
% Change Since:
|
Earnings Call Sentiment|Positive
The call highlighted a decisive strategic move — the Kashiv acquisition — that meaningfully expands Amneal's addressable market, vertical capabilities, and long‑term growth runway in biosimilars. Q1 results showed strong top‑ and bottom‑line execution (revenues +4%, adjusted EBITDA +19%, adjusted EPS +29%), margin expansion, specialty product momentum, and improving leverage. Near‑term challenges include transaction‑related cash/financing impacts, modest near‑term dilution and guidance cadence (some 2027 EBITDA conservatism), integration and execution risk inherent to complex biologics development, and required CapEx to scale capacity. On balance, the positives around scale, pipeline, synergies ($400M–$500M), and improved long‑term financial trajectory outweigh the short‑term costs and execution risks.Company Guidance
Strategic Acquisition Creating a Global Biosimilars Platform
Amneal announced agreement to acquire Kashiv BioSciences (upfront consideration $750M: 50% cash / 50% equity, ~8% dilution; up to $350M in milestone payments and potential royalties), creating a vertically integrated biosimilars leader with a combined pipeline of 20+ biosimilar programs and access to what management cited as more than $300M of biologic LOE opportunity over the next decade and a broader $100B+ U.S. opportunity across the portfolio.
Robust Q1 2026 Financial Performance
Preliminary Q1 results: total net revenues $723M (+4% year-over-year), adjusted EBITDA $202M (+19% YoY), adjusted EPS $0.27 (+29% YoY). Affordable Medicines revenue $423M (+2% YoY) and Specialty revenue $133M (+23% YoY).
Margin Expansion and Operating Leverage
Q1 segment gross margin for Affordable Medicines was 47.3% (up 320 basis points vs Q1 2025). Management reported adjusted gross margins expanded ~500 basis points driving strong EBITDA leverage. Full‑year gross margin target raised to approximately 45% for 2026 (vs ~43% in 2025, ~200 bps expansion expected).
Pipeline and Launch Cadence
Management expects multiple biosimilar launches annually with a clear near‑term cadence: 6 commercial biosimilars by 2027 (including Avastin and Denosumab; XOLAIR pending approval), lanreotide expected approval in Q3, XOLAIR targeted year‑end approval, and 6+ additional approvals from advanced pipeline by 2030.
Manufacturing Capacity and Scalability
Kashiv provides 4 R&D/manufacturing sites, ~600 employees and >$900M historical investment; drug substance capacity expected to scale from 26,000 liters in 2026 to 75,000 liters by 2028, with additional incremental CapEx of roughly $30M–$50M per year for the next 2–3 years to reach that scale.
Financial Synergies and Long-Term Growth Targets
Management expects $400M–$500M in cumulative financial synergies over time. Long-term combined outlook: by 2030 revenues expected to grow by approximately $1.2B (≈40% over 2026) and EPS up approximately $0.70 (≈70% over 2026). Company guidance for 2030 revenue range $4.3B–$4.5B, with biosimilars expected to contribute approximately $1.0B–$1.3B by 2030.
Improving Leverage Despite Deal Funding
Net leverage improved to 3.5x adjusted EBITDA in March 2026 (from 3.9x in March 2025). The transaction is expected to result in combined net debt leverage of ~3.7x at end‑2026, with a clear path to deleverage to below 3x by 2028.
Specialty Launch Momentum
Strong early specialty product traction: CREXONT revenue $21M in Q1 with favorable Phase IV data; Brekiya launch revenue $4.6M in Q1 (vs $1.6M in Q4 2025) indicating rapid adoption.
AMRX Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
AMRX Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 01, 2026 | $12.87 | $12.83 | -0.31% |
Feb 27, 2026 | $14.49 | $13.81 | -4.69% |
Oct 30, 2025 | $10.43 | $10.00 | -4.12% |
Aug 05, 2025 | $7.96 | $8.13 | +2.14% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Amneal Pharmaceuticals Inc (AMRX) report earnings?
Amneal Pharmaceuticals Inc (AMRX) is schdueled to report earning on Aug 12, 2026, Before Open (Confirmed).
What is Amneal Pharmaceuticals Inc (AMRX) earnings time?
Amneal Pharmaceuticals Inc (AMRX) earnings time is at Aug 12, 2026, Before Open (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is AMRX EPS forecast?
AMRX EPS forecast for the fiscal quarter 2026 (Q2) is 0.23.
